SELECTED ABSTRACTS FOR POSTER PRESENTATIONS
IN ALPHABETIC ORDER ACCORDING TO THE NAME OF THE FIRST AUTHOR
CLINICAL POSTERS
Poster 1: ACUTE LYMPHOBLASTIC LEUKEMIC TRANSFORMATION FROM PRIMARY
MYELOFIBROSIS
Carolina Afonso, Rita Gomes, Sara Duarte, Bárbara Marques, José Pedro Carda, Letícia
Ribeiro
Poster 2: PROGNOSTIC SIGNIFICANCE OF BCR/ABL REARRANGEMENTS BY INTERPHASE
FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN CML AND ALL
Zeeshan Ahemd
Poster 3: STOP INTERFERON: A CASE OF SUSTAINED MOLECULAR RESPONSE IN
CHRONIC MYELOID LEUKAEMIA AFTER TREATMENT DISCONTINUATION
Pedro Baptista, Ricardo Pinto, Mariana Lopes, Maria Luís Amorim, Manuel Sobrinho
Simões, José Eduardo Guimarães, Fernanda Trigo
Poster 4: MYELOPROLIFERATIVE DISEASES: TWO DIAGNOSIS IN THE SAME PATIENT
Maria Eduarda Couto, Isabel Oliveir, José Mariz
Poster 5: A CRYPTIC CYTOGENETIC REARRANGEMENT IN CML
Maria Eduarda Couto, Nuno Cerveira, Cecília Correia, Susana Bizarro, Susana Lisboa,
Manuel Teixeira, José Mariz
Poster 6: EFFICACY AND SAFETY OF RUXOLITINIB IN MYELOFIBROSIS – A SINGLE
CENTER EXPERIENCE
Sara Duarte, Diana Mota, Mónica Santos, Rita S. Gomes, José Pedro Carda, Letícia
Ribeiro
P
oster 7: COOCCURRENCE OF MYELOID AND LYMPHOID NEOPLASMS IS ASSOCIATED
WITH INFECTIOUS COMPLICATIONS AND WORSE OUTCOME. A SINGLE-CENTER
COHORT STUDY
Bruno Fattizzo, Cristina Bucelli, Daniele Cattaneo, Kordelia Barbullushi, Raffaella
Pasquale, Loredana Pettine, Francesca Gaia Rossi, Gianluigi Reda, Luca Baldini,
Alessandra Iurlo
P
oster 8: CLONAL EVOLUTION OF MPN: A CASE REPORT
Rita S. Gomes, Sara Duarte, Diana Mota, Ana T Simões, Margarida Coucelo, José Carda,
Letícia Ribeiro
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES